Repositori institucional de la UVic-UCC: Recent submissions
Now showing items 1521-1540 of 7135
-
Caracterització funcional i computacional de mutacions dels gens grins
(2023-06-30)Keywords: Glutamatergic synapse, NMDA receptor, GRIN, disease-associated mutations. Glutamatergic synapse is crucial for synaptic plasticity, neuronal development, learning, and memory. Glutamate ... -
Estudi de mètodes de deconvolució
(2023-01-30)La Deconvolució és una eina computacional que permet identificar i quantificar els tipus cel·lulars presents en una matriu d’expressió d'una mostra bulk o mixta. Actualment, aquesta tècnica es pot dur ... -
Valorització de subproductes de la indústria de begudes vegetals com a medi de cultiu per la producció de proteïnes unicel·lulars
(2023-06-01)Segons les xifres de la Unió Europea (UE), es generen 88 milions de tones a l'any de residus alimentaris que suposen un 20% dels aliments produïts. D'aquests 88 milions, un 19% prové del processament ... -
The Incorporation of Cultural and Religious Diversity in LGBT Policies: Experiences of Queer Migrants from Muslim Backgrounds in Catalonia, Spain
(2022)This article reflects on the biases in sexual and gender diversity policies in relation to the axis of cultural and religious diversity in Catalonia (Spain), where these policies have experienced an ... -
Cell compartment isoform expression analysis using long-read transcriptomics
(2023-09-01)Motivation: Alternative splicing, a crucial post-transcriptional process, enhances proteomic diversity without increasing gene numbers, playing pivotal roles in gene regulation, specialization, and ... -
Host epigenetic changes to Salmonella Paratyphi exposure
(2023-09-10)Motivation: Typhoid fever, resulting from Salmonella enterica serovars Typhi and Paratyphi A, stands as a significant contributor to illness and mortality. Recent challenge studies on the host immunity ... -
Doing, being and verbalizing: Narratives of queer migrants from Muslim backgrounds in Spain
(2021)The hegemonic narrative in the West establishes that having same-sex relationships constitutes an identity that must be public. This article analyses how this narrative is reproduced and/or subverted ... -
Unveiling distinct features of long-term benefit in metastatic NSCLC patients undergoing immune checkpoint blockade
(2023-09-01)Introduction: Immunotherapy is firmly established as a treatment regimen in various solid tumors, driven by its exceptional benefits observed in a select group of patients. Despite widespread use of ... -
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial
(2018)IMPORTANCE Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some ... -
Transcriptomic analysis of BRCA1 and BRCA2 carriers
(2023-09-01)Most frequently mutations that lead to the development of breast and ovarian cancer are BRCA1 and BRCA2. Blood samples from BRCA1, BRCA2 and non-mutation carriers were extracted for both healthy and ... -
Lipid metabolism as a therapeutic vulnerability in medulloblastoma
(2023-09-01)Medulloblastoma (MB) is the most common malignant brain tumor in children and presents a varied prognosis, with some patients succumbing to the disease and survivors presenting neurotoxic sequelae from ... -
Binimetinib Encorafenib and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
(2019)To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, ... -
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
(2018)Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or ... -
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
(2019)Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR ... -
Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors
(2019)Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age >= 18 years with advanced solid tumors for which ... -
Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
(2020)IMPORTANCE Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE To evaluate the antitumor activity of pembrolizumab, ... -
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study
(2021)PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E-mutant metastatic ... -
HRAS physical feature analysis: Predicting protein activation through a random forest classifier
(2023-09-10)Over the past decade, increased computational capabilities have enabled us to address biological questions using data-driven methods, particularly where traditional techniques have been limiting. We ... -
A CITE-seq analytical pipeline for the identification and molecular characterisation of dual targeting CAR T-cell products
(2023-09-01)The clinical application of T-cells genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19 is challenged by CD19 negative relapse in B-cell acute lymphoblastic leukaemia (B-ALL). ...